ArticleiLIVER2022
Ascorbic acid ameliorates isoniazid-rifampicin-induced hepatocellular damage in rats.
Article in iLIVER, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic dynamics and stage-specific biomarkers in chronic HBV infection: a metabolomics study.BMC gastroenterology · 2025Article
- Risk factors related to significant hepatic inflammation in patients with acute drug-induced liver injury.iLIVER · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Phyto-constituents are widely recognized for hepatoprotective effects. Ascorbic acid is extensively studied for the radical scavenging effect. The objective of the present study was to evaluate the hepatoprotective effect of ascorbic acid against isoniazid and rifampicin-induced liver damage in rats. Methods: Wistar rats were used in the present study. Hepato-cellular damage was produced by the administration of isoniazid (100 mg/kg) and rifampicin (100 mg/kg) for 21 days. Ascorbic acid was administered in the dose of 50, 100, and 200 mg/kg body weight. At the end of the study, blood was collected and biochemical studies were performed to determine antioxidant status. Results: Ascorbic acid administration (50, 100, and 200 mg/kg body weight) caused restoration of serum glutamic oxaloacetic transaminase, serum glutamic-pyruvic transaminase, and serum alkaline phosphatase. The level of superoxide dismutase and catalase were also restored due to the administration of ascorbic acid. There was a decrement in the expression of tumor necrosis factor-α, interleukin-1β, interleukin-6, malondialdehyde and nitric oxide. Conclusion: The outcome of the study established ascorbic acid as a notable hepatoprotective effect. The radical scavenging and cytokine suppression effect is the possible mechanism associated with the hepatoprotective effect of ascorbic acid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.